For the millions of stroke patients who arrive at emergency departments outside the traditional 4.5-hour treatment window, expanding thrombolytic therapy options could be transformative. The OPTION trial's investigation of tenecteplase in this extended timeframe directly challenges the long-standing assumption that clot-busting drugs lose their utility — and safety margin — beyond that threshold.
The OPTION trial evaluated intravenous tenecteplase administered between 4.5 and 24 hours post-ischemic stroke onset in patients without large vessel occlusion, using CT perfusion imaging to select eligible candidates. This imaging-guided patient selection strategy mirrors the approach validated in trials like WAKE-UP and EXTEND, where perfusion mismatch ratios helped identify viable penumbral tissue. The correspondence published in JAMA raises specific concerns about the safety profile observed in this extended-window cohort, urging careful interpretation of the efficacy signals in light of potential hemorrhagic risks and clinical context variables.
This commentary sits within a rapidly evolving thrombolysis landscape. Tenecteplase has already demonstrated non-inferiority to alteplase in the standard treatment window, with practical advantages including single-bolus administration. However, extending its use to the 4.5–24 hour window in non-large vessel occlusion strokes introduces a distinctly different risk-benefit calculus. The penumbra is smaller and less predictable at later time points, and CT perfusion imaging, while powerful, carries well-documented variability in automated software outputs. The safety concerns raised here — likely centered on symptomatic intracranial hemorrhage rates — echo cautionary findings from earlier extended-window alteplase trials. For clinicians, this underscores that imaging selection does not uniformly mitigate hemorrhagic risk when time from onset extends substantially. This appears to be an incremental but important contribution: not paradigm-shifting on its own, but a necessary brake on premature protocol adoption before larger, prospective replication confirms an acceptable safety threshold.